| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2002/014061WO2004052333A1 (en) | 2002-12-11 | 2002-12-11 | Pharmaceutical compositions for the pulmonary delivery of aztreonam |
| Publication Number | Publication Date |
|---|---|
| AU2002356646A1true AU2002356646A1 (en) | 2004-06-30 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002356646AAbandonedAU2002356646A1 (en) | 2002-12-11 | 2002-12-11 | Pharmaceutical compositions for the pulmonary delivery of aztreonam |
| Country | Link |
|---|---|
| AU (1) | AU2002356646A1 (en) |
| WO (1) | WO2004052333A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW465235B (en) | 1998-09-17 | 2001-11-21 | United Video Properties Inc | Electronic program guide with digital storage |
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| US7138419B2 (en)* | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
| DK2301524T3 (en) | 2000-12-27 | 2013-07-15 | Gilead Sciences Inc | INHALABLE AZTREONAM WITHOUT ARGININE FOR TREATMENT AND PREVENTION OF BACTERIAL LUNG INFECTIONS |
| KR100687001B1 (en) | 2002-08-05 | 2007-02-27 | 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 | Aztreonam recipe |
| US7452991B2 (en) | 2003-05-15 | 2008-11-18 | Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság | Aztreonam β polymorph with very low residual solvent content |
| CA2531170C (en) | 2003-07-02 | 2011-05-10 | Teva Gyogyszergyar Reszvenytarsasag | Aztreonam l-lysine and methods for the preparation thereof |
| AU2014271333B2 (en)* | 2003-07-03 | 2016-10-27 | Gilead Sciences, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| CA2606901A1 (en) | 2005-05-09 | 2006-11-16 | Sicor Inc. | Process for making aztreonam |
| CA2622193A1 (en) | 2005-09-29 | 2007-04-12 | Nektar Therapeutics | Antibiotic formulations, unit doses, kits, and methods |
| US8337814B2 (en) | 2005-12-15 | 2012-12-25 | Topical Sinus Therapeutics, Inc. | Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions |
| NZ728487A (en)* | 2014-08-08 | 2021-07-30 | Shenzhen Hightide Biopharmaceutical Ltd | Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof |
| CN104784159A (en)* | 2015-04-15 | 2015-07-22 | 苏州惠仁生物科技有限公司 | Method for preparing aztreonam powder aerosol |
| CN110898040B (en)* | 2018-09-18 | 2022-05-17 | 北京盈科瑞创新药物研究有限公司 | Freeze-dried powder for aztreonam solution for inhalation and preparation method thereof |
| CN113876722B (en)* | 2021-11-04 | 2022-12-02 | 海南皇隆制药股份有限公司 | Aztreonam for injection and preparation method thereof |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1181075A (en)* | 1981-07-13 | 1985-01-15 | David M. Floyd | CRYSTALLINE ANHYDROUS FORM OF [3-S-[3.alpha.(Z),4 .beta.]]-3-[[(2-AMINO-4-THIAZOLYL) [(1-CARBOXY-1-METHYLETHOXY)IMINO]ACETYL] AMINO]-4-METHYL-2-OXO-1-AZETIDINESULFONIC ACID |
| US4826973A (en)* | 1984-07-20 | 1989-05-02 | E. R. Squibb & Sons, Inc. | Delta form of aztreonam and preparation thereof |
| US4675398A (en)* | 1985-08-16 | 1987-06-23 | E. R. Squibb & Sons, Inc. | Copper-mediated oximation reaction |
| CA1339136C (en)* | 1987-07-01 | 1997-07-29 | Sailesh Amilal Varia | Amorphous form of aztreonam |
| WO2001034128A2 (en)* | 1999-11-08 | 2001-05-17 | Pharmacia & Upjohn Company | Admixture for intravenous administration of linezolid and other antibacterial agents |
| DK2301524T3 (en)* | 2000-12-27 | 2013-07-15 | Gilead Sciences Inc | INHALABLE AZTREONAM WITHOUT ARGININE FOR TREATMENT AND PREVENTION OF BACTERIAL LUNG INFECTIONS |
| Publication number | Publication date |
|---|---|
| WO2004052333A1 (en) | 2004-06-24 |
| Publication | Publication Date | Title |
|---|---|---|
| AU2003278393A1 (en) | New use for pharmaceutical composition | |
| AU2003291103A1 (en) | Pharmaceutical composition | |
| GB2389530B (en) | Pharmaceutical compositions | |
| IL163366A (en) | Glucocorticoid mimetics, pharmaceutical compositions thereof and uses thereof for the preparation of pharmaceutical compositions | |
| AU2003246810A1 (en) | Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives | |
| AU2003245504A1 (en) | Pharmaceutical compositions for drugs having ph-dependentsolubility | |
| AU2003250372A1 (en) | Pharmaceutical composition | |
| AU2002356646A1 (en) | Pharmaceutical compositions for the pulmonary delivery of aztreonam | |
| AU2001232017A1 (en) | Pharmaceutical composition for pulmonary delivery | |
| GB0213481D0 (en) | Pharmaceutical compositions | |
| AU2003265373A1 (en) | Preparation of aztreonam | |
| AU2003216503A1 (en) | Stable pharmaceutical compositions | |
| AU2003274410A1 (en) | Pharmaceutical compositions of ganciclovir | |
| AU2003238896A1 (en) | Stabilized pharmaceutical compositions containing benzimidazole compounds | |
| AU2003280960A1 (en) | Pharmaceutical compositions for otic use | |
| AU2003205460A1 (en) | Liquid mucoadhesive pharmaceutical composition | |
| SI1653963T1 (en) | Nasal pharmaceutical piribedil composition | |
| AUPS188302A0 (en) | Pharmaceutical composition | |
| AU2003201624A1 (en) | Compositions for pulmonary administration | |
| AU2002236132A1 (en) | Modified release oral pharmaceutical composition | |
| HK1078272A (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| HK1073611A (en) | Pharmaceutical compositions | |
| HK1067075A (en) | Microparticle pharmaceutical compositions for intratumoral delivery | |
| HK1071299A (en) | Stable pharmaceutical compositions | |
| AU2001290947A1 (en) | Compositions for drug delivery |
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |